223 related articles for article (PubMed ID: 25365349)
1. 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.
Higashikawa K; Yagi K; Watanabe K; Kamino S; Ueda M; Hiromura M; Enomoto S
PLoS One; 2014; 9(11):e109866. PubMed ID: 25365349
[TBL] [Abstract][Full Text] [Related]
2. Monitoring CD8a
Kristensen LK; Christensen C; Alfsen MZ; Cold S; Nielsen CH; Kjaer A
Mol Imaging Biol; 2020 Aug; 22(4):1021-1030. PubMed ID: 32086762
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
4. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.
Ehlerding EB; England CG; Majewski RL; Valdovinos HF; Jiang D; Liu G; McNeel DG; Nickles RJ; Cai W
Mol Pharm; 2017 May; 14(5):1782-1789. PubMed ID: 28388076
[TBL] [Abstract][Full Text] [Related]
6. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
10. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.
Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999
[TBL] [Abstract][Full Text] [Related]
11. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
[TBL] [Abstract][Full Text] [Related]
12. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide.
Nielsen CH; Kimura RH; Withofs N; Tran PT; Miao Z; Cochran JR; Cheng Z; Felsher D; Kjær A; Willmann JK; Gambhir SS
Cancer Res; 2010 Nov; 70(22):9022-30. PubMed ID: 21062977
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
16. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
17. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.
Cheng Z; Xiong Z; Subbarayan M; Chen X; Gambhir SS
Bioconjug Chem; 2007; 18(3):765-72. PubMed ID: 17348700
[TBL] [Abstract][Full Text] [Related]
18. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.
Cai W; Chen K; He L; Cao Q; Koong A; Chen X
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):850-8. PubMed ID: 17262214
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.
Wei L; Butcher C; Miao Y; Gallazzi F; Quinn TP; Welch MJ; Lewis JS
J Nucl Med; 2007 Jan; 48(1):64-72. PubMed ID: 17204700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
